Dr. Melnick on the Future of Chemotherapy in Lymphomas

Video

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses the future of chemotherapy in patients with lymphomas.

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses the future of chemotherapy in patients with lymphomas.

Melnick believes that chemotherapy is not required to cure lymphomas. Similar to other tumor types, lymphomas are dependent on several biological factors to survive and grow.

Lymphomas depend on lineage factors: proteins that are present without which the disease cannot survive. Further, somatic mutations occur in lymphomas and are targetable or represent targetable pathways. It is possible, Melnick says, to eradicate all lymphoma cells with targeted agents or various combinations of targeted agents. It is also becoming increasingly possible for agents to erase "instructions" (epigenetic settings) to destroy the disease.

Targeting pathways, lineage factors, and epigenetic settings provide physicians with three ways to combat lymphomas.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Annie Im, MD, FASCO
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology